Your browser doesn't support javascript.
From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era.
Miao, Ganggang; Chen, Zhiqiang; Cao, Hengsong; Wu, Wenhao; Chu, Xi; Liu, Hanyuan; Zhang, Leyao; Zhu, Hongfei; Cai, Hongzhou; Lu, Xiaolan; Shi, Junfeng; Liu, Yuan; Feng, Tingting.
  • Miao G; Department of General Surgery, The People's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Danyang, China; Department of General Surgery, The Affiliated Nanjing Hospital of Nanjing Medical University, Nanjing, China.
  • Chen Z; Department of Nuclear Medicine, The First Affiliated Hospital of Suzhou University, Suzhou, China.
  • Cao H; Department of General Surgery, The Affiliated Nanjing Hospital of Nanjing Medical University, Nanjing, China.
  • Wu W; Department of Clinical Medicine, Nanjing Medical University The First School of Clinical Medicine, Nanjing, China.
  • Chu X; Department of Radiology, Nanjing Medical University The Fourth School of Clinical Medicine, Nanjing, China.
  • Liu H; Department of General Surgery, The Affiliated Nanjing Hospital of Nanjing Medical University, Nanjing, China.
  • Zhang L; Department of Clinical Medicine, Nanjing Medical University The First School of Clinical Medicine, Nanjing, China.
  • Zhu H; Department of Clinical Medicine, Nanjing Medical University The First School of Clinical Medicine, Nanjing, China.
  • Cai H; Department of Urology, Jiangsu Cancer Hospital &The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research, Nanjing, China. Electronic address: caihongzhou@njmu.edu.cn.
  • Lu X; Department of Clinical laboratory, Canglang Hospital of Suzhou, Suzhou, China. Electronic address: orangexxlu@hotmail.com.
  • Shi J; Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China; Department of Molecular and Celluar Biochemistry, Markey Cancer Center, University of Kentucky, Lexington, KY, USA. Electronic address: jsh316@uky.edu.
  • Liu Y; Department of Infectious Disease,The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. Electronic address: liuyuan@njmu.edu.cn.
  • Feng T; Jiangsu Key Laboratory of Infection and Immunity, Institute of Biology and Medical Sciences, Soochow University, Suzhou, China. Electronic address: ttfeng@suda.edu.cn.
Biomed Pharmacother ; 158: 114208, 2023 Feb.
Artigo em Inglês | MEDLINE | ID: covidwho-2233274
ABSTRACT
The COVID-19 pandemic has affected millions of people and posed an unprecedented burden on healthcare systems and economies worldwide since the outbreak of the COVID-19. A considerable number of nations have investigated COVID-19 and proposed a series of prevention and treatment strategies thus far. The pandemic prevention strategies implemented in China have suggested that the spread of COVID-19 can be effectively reduced by restricting large-scale gathering, developing community-scale nucleic acid testing, and conducting epidemiological investigations, whereas sporadic cases have always been identified in numerous places. Currently, there is still no decisive therapy for COVID-19 or related complications. The development of COVID-19 vaccines has raised the hope for mitigating this pandemic based on the intercross immunity induced by COVID-19. Thus far, several types of COVID-19 vaccines have been developed and released to into financial markets. From the perspective of vaccine use in globe, COVID-19 vaccines are beneficial to mitigate the pandemic, whereas the relative adverse events have been reported progressively. This is a review about the development, challenges and prospects of COVID-19 vaccines, and it can provide more insights into all aspects of the vaccines.
Assuntos
Palavras-chave

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Estudo observacional Tópicos: Vacinas Limite: Humanos País/Região como assunto: Ásia Idioma: Inglês Revista: Biomed Pharmacother Ano de publicação: 2023 Tipo de documento: Artigo País de afiliação: J.biopha.2022.114208

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Estudo observacional Tópicos: Vacinas Limite: Humanos País/Região como assunto: Ásia Idioma: Inglês Revista: Biomed Pharmacother Ano de publicação: 2023 Tipo de documento: Artigo País de afiliação: J.biopha.2022.114208